← Volver a la portada
Estados Unidos · Agencias y tiempo real · PR Newswire

Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

Publicado por PR Newswire · Estados Unidos hace 1 h

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

También te puede interesar

Business Wire

Peoples Security Bank & Trust Welcomes Scott Campagna as Executive Vice President, Chief Information Officer

 Associated Press (Business)

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

 Dow Jones Newswires

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

 MT Newswires

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows